Company Overview - Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare genetic skin diseases that lack FDA-approved treatments [4] - The company is developing a pipeline of product candidates based on its patented QTORIN™ platform, with its lead product candidate being QTORIN™ 3.9% rapamycin anhydrous gel, currently in Phase 3 and Phase 2 clinical trials [4] Market Position - Palvella has been added to the Russell 3000 Index and the Russell 2000 Index, effective June 30, 2025, as part of the annual Russell indexes reconstitution [1][2] - Membership in the Russell 3000 Index indicates automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index, which is significant for market visibility and investment opportunities [2] Industry Context - The Russell indexes are widely utilized by investment managers and institutional investors for index funds and as benchmarks for active investment strategies, with approximately $10.6 trillion in assets benchmarked against these indexes as of June 2024 [3]
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
Globenewswire·2025-06-30 11:30